Pub Date : 2021-01-07DOI: 10.1007/s13671-020-00326-x
Lori S Kim, Jashin J. Wu, G. Han
{"title":"Deucravacitinib for Psoriasis","authors":"Lori S Kim, Jashin J. Wu, G. Han","doi":"10.1007/s13671-020-00326-x","DOIUrl":"https://doi.org/10.1007/s13671-020-00326-x","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"10 1","pages":"1 - 5"},"PeriodicalIF":1.6,"publicationDate":"2021-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00326-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46784936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-06DOI: 10.1007/s13671-020-00327-w
N. Brownstone, T. Bhutani, J. Koo
{"title":"Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis","authors":"N. Brownstone, T. Bhutani, J. Koo","doi":"10.1007/s13671-020-00327-w","DOIUrl":"https://doi.org/10.1007/s13671-020-00327-w","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"10 1","pages":"21-25"},"PeriodicalIF":1.6,"publicationDate":"2021-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00327-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49084271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-04DOI: 10.1007/s13671-020-00325-y
E. Hadeler, M. Mosca, Julie J. Hong, N. Brownstone, T. Bhutani, W. Liao
{"title":"Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors","authors":"E. Hadeler, M. Mosca, Julie J. Hong, N. Brownstone, T. Bhutani, W. Liao","doi":"10.1007/s13671-020-00325-y","DOIUrl":"https://doi.org/10.1007/s13671-020-00325-y","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"1 1","pages":"1-10"},"PeriodicalIF":1.6,"publicationDate":"2021-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00325-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46462842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-04DOI: 10.1007/s13671-020-00324-z
N. Brownstone, M. Mosca, Julie J. Hong, E. Hadeler, T. Bhutani
{"title":"Phototherapy for Psoriasis: New Research and Insights","authors":"N. Brownstone, M. Mosca, Julie J. Hong, E. Hadeler, T. Bhutani","doi":"10.1007/s13671-020-00324-z","DOIUrl":"https://doi.org/10.1007/s13671-020-00324-z","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"1 1","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2021-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00324-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46784604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01Epub Date: 2021-03-12DOI: 10.1007/s13671-021-00329-2
Spandana Maddukuri, Jay Patel, Jules B Lipoff
Purpose of review: Dermatologists have been at the forefront of researching telemedicine to expand access to care. The current COVID-19 pandemic has prompted even greater expansion and implementation of teledermatology. This review discusses the research examining the potential impact of teledermatology addressing disparities in care.
Recent findings: Teledermatology appears to increase access to dermatology given expanded means to deliver care. Specifically, recent studies have found increased access among Medicaid-insured, resource-poor urban and rural, and elderly populations. Teledermatology implementation also facilitates education among providers at different levels of training. Still, as some patients have inconsistent access to the required technology, increased reliance on telemedicine may also potentially increase disparities for some populations.
Summary: Teledermatology may serve to reduce disparities in health care access in many underserved and marginalized communities. Future research should continue to study implementation, especially given the expansion during the COVID-19 pandemic. Ultimately, teledermatology may play an important role in ensuring equitable care access for all.
{"title":"Teledermatology Addressing Disparities in Health Care Access: a Review.","authors":"Spandana Maddukuri, Jay Patel, Jules B Lipoff","doi":"10.1007/s13671-021-00329-2","DOIUrl":"https://doi.org/10.1007/s13671-021-00329-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Dermatologists have been at the forefront of researching telemedicine to expand access to care. The current COVID-19 pandemic has prompted even greater expansion and implementation of teledermatology. This review discusses the research examining the potential impact of teledermatology addressing disparities in care.</p><p><strong>Recent findings: </strong>Teledermatology appears to increase access to dermatology given expanded means to deliver care. Specifically, recent studies have found increased access among Medicaid-insured, resource-poor urban and rural, and elderly populations. Teledermatology implementation also facilitates education among providers at different levels of training. Still, as some patients have inconsistent access to the required technology, increased reliance on telemedicine may also potentially increase disparities for some populations.</p><p><strong>Summary: </strong>Teledermatology may serve to reduce disparities in health care access in many underserved and marginalized communities. Future research should continue to study implementation, especially given the expansion during the COVID-19 pandemic. Ultimately, teledermatology may play an important role in ensuring equitable care access for all.</p>","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"10 2","pages":"40-47"},"PeriodicalIF":1.6,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-021-00329-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25513240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01Epub Date: 2021-07-28DOI: 10.1007/s13671-021-00333-6
Karen McKoy, Saul Halpern, Kudakwashe Mutyambizi
Purpose of review: The use of teledermatology has been evolving slowly for the delivery of health care to remote and underserved populations. Improving technology and the recent COVID-19 pandemic have hastened its use internationally.
Recent findings: Some barriers to the use of teledermatology have fallen considerably in the last year.
Summary: Teledermatology use has increased significantly in recent years in both government-sponsored and private health care systems and individual practices. There are no recognized international practice guidelines and variable use within countries. Many barriers remain to increasing the use of teledermatology.
{"title":"International Teledermatology Review.","authors":"Karen McKoy, Saul Halpern, Kudakwashe Mutyambizi","doi":"10.1007/s13671-021-00333-6","DOIUrl":"https://doi.org/10.1007/s13671-021-00333-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>The use of teledermatology has been evolving slowly for the delivery of health care to remote and underserved populations. Improving technology and the recent COVID-19 pandemic have hastened its use internationally.</p><p><strong>Recent findings: </strong>Some barriers to the use of teledermatology have fallen considerably in the last year.</p><p><strong>Summary: </strong>Teledermatology use has increased significantly in recent years in both government-sponsored and private health care systems and individual practices. There are no recognized international practice guidelines and variable use within countries. Many barriers remain to increasing the use of teledermatology.</p>","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"10 3","pages":"55-66"},"PeriodicalIF":1.6,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-021-00333-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39270391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1007/s13671-021-00348-z
Elisa Maria Schunkert, Sherrie Jill Divito
Purpose of review: To provide updates on recent advances in the diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Recent findings: The number of identified HLA allele associations with DRESS continues to grow. There is increasing evidence indicating viral infection, reactivation, and cross-reactivity may play key roles in disease. Translational work illuminated JAK/STAT activation in recalcitrant disease. There is expanding recognition of rapid-onset DRESS resulting from specific drugs.
Summary: DRESS is a severe form of adverse drug reaction with potential for significant morbidity and mortality. Recent research advances may improve clinical care. HLA screening can now be performed to prevent disease in susceptible patients and may help identify culprit drugs in the near future. Viral testing should be performed on every patient, and if positive, patients potentially treated with antiviral therapy. JAK inhibitors may be an effective treatment option for DRESS. Early onset of disease relative to drug exposure should not exclude the diagnosis of DRESS.
{"title":"Updates and Insights in the Diagnosis and Management of DRESS Syndrome.","authors":"Elisa Maria Schunkert, Sherrie Jill Divito","doi":"10.1007/s13671-021-00348-z","DOIUrl":"https://doi.org/10.1007/s13671-021-00348-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide updates on recent advances in the diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.</p><p><strong>Recent findings: </strong>The number of identified HLA allele associations with DRESS continues to grow. There is increasing evidence indicating viral infection, reactivation, and cross-reactivity may play key roles in disease. Translational work illuminated JAK/STAT activation in recalcitrant disease. There is expanding recognition of rapid-onset DRESS resulting from specific drugs.</p><p><strong>Summary: </strong>DRESS is a severe form of adverse drug reaction with potential for significant morbidity and mortality. Recent research advances may improve clinical care. HLA screening can now be performed to prevent disease in susceptible patients and may help identify culprit drugs in the near future. Viral testing should be performed on every patient, and if positive, patients potentially treated with antiviral therapy. JAK inhibitors may be an effective treatment option for DRESS. Early onset of disease relative to drug exposure should not exclude the diagnosis of DRESS.</p>","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"10 4","pages":"192-204"},"PeriodicalIF":1.6,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10502345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-11DOI: 10.1007/s13671-020-00322-1
Rhea Singh, Esther A. Balogh, S. Feldman
{"title":"Update on IL-17 Inhibitors for Psoriasis","authors":"Rhea Singh, Esther A. Balogh, S. Feldman","doi":"10.1007/s13671-020-00322-1","DOIUrl":"https://doi.org/10.1007/s13671-020-00322-1","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"9 1","pages":"339 - 352"},"PeriodicalIF":1.6,"publicationDate":"2020-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00322-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44905366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-10DOI: 10.1007/s13671-020-00318-x
Stephanie A McNamara, B. A. Cahn, M. Sanders, Alberto J. Lopez
{"title":"Venous Procedures to Treat Venous Leg Ulcers","authors":"Stephanie A McNamara, B. A. Cahn, M. Sanders, Alberto J. Lopez","doi":"10.1007/s13671-020-00318-x","DOIUrl":"https://doi.org/10.1007/s13671-020-00318-x","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"9 1","pages":"277 - 285"},"PeriodicalIF":1.6,"publicationDate":"2020-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00318-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45471898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-07DOI: 10.1007/s13671-020-00320-3
Sydney R. Resnik, Andjela Egger, B. Abdo Abujamra, I. Jozic
{"title":"Clinical Implications of Cellular Senescence on Wound Healing","authors":"Sydney R. Resnik, Andjela Egger, B. Abdo Abujamra, I. Jozic","doi":"10.1007/s13671-020-00320-3","DOIUrl":"https://doi.org/10.1007/s13671-020-00320-3","url":null,"abstract":"","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"9 1","pages":"286 - 297"},"PeriodicalIF":1.6,"publicationDate":"2020-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13671-020-00320-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43076911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号